ARTICLE BY LOUIS

• Innovators In The Pharmaceutical Packaging Industry

  12/14/2015

  As biologics and global injectable-drug markets grow, BioPharma needs advancements ensuring the highest quality in the integration of new delivery systems and packaging technologies that can be administered outside of clinical settings. Service providers are responding.

• So A New Drug Takes $1 Billion?

  6/11/2015

  Here’s a position that addresses the various sides of the clinical trial discussion, and binds this front-end activity of the "billion-dollar debate" to the subsequent, downstream measurement of the real economic value, and safety, of new drugs.

• Marking The Present And Promise of Biomarkers

  6/4/2015

  Biomarkers are becoming an industry unto themselves: they have their own FDA tables and World Congress, and have been before the Supreme Court. They also provide outsourcing companies with growing business opportunities. At the same time, it’s good practice to temper enthusiasm with a reality-check on the real-world status of the development and application of any science. 

• A Cost Measurement Pharma Can Live With (CROs/CMOs, Too)

  6/2/2015

  Sometimes one finds help in unusual places. This might be one of those times for Pharma, and the place could be AdverseEvents. And Pharma can turn to a more usual partner — CROs/CMOs — to positively influence what AdverseEvents measures.

• CROs In A Business Exchange With Silicon Valley?

  5/29/2015

  As an applied economic theoretic, by driving out inefficiencies from the current model used by researchers to find and contract with CROs, the Science Exchange should improve the business model for drug discovery. But will all parties — Pharma/Bio, CROs and individual researchers — benefit equally? 

• Measure Lives Gilead Returns, And The Returns It Provides

  3/24/2015

  Reporting on the cost of Sovaldi (Sofosbuvir) has confused price and value. Gilead isn't bankrupting healthcare; it's bankrolling the system. When we turn negative on a company like Gilead, we turn on our own well-being. 

• A Trait For Quailty In John McKay's DNA

  9/24/2014

  If you string together some of John McKay’s qualifications, they form what looks something like a strand of DNA from a new life form: CMQCQAQMS. And this particular gene would express a single trait: McKay knows quality like few others.

• Serial Entrepreneur Points To Initial Funding Sources For Biotechs

  9/24/2014

  Kevin Judice lists himself on LinkedIn as “Entrepreneur.” Perhaps he has to; there just isn’t enough space to include the three companies he recently started and at which he concurrently is employed as CEO or CSO.

• A Global Forum For Outsourcing (With Simple Objectives)

  9/24/2014

  Perhaps the best advice I’ve heard regarding industry conferences is twofold: first, make sure you attend, and second, keep your objectives for attending simple.

• Lean Six Sigma From An Outsourcing Industry Raconteur

  8/29/2014

  Bikash Chatterjee knows all about Lean Six Sigma. He’ll share that wisdom with us at Outsourced Pharma West in San Francisco, November 11-12. However, you might not notice when he’s doing it.